Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Maia Harvey"'
Autor:
Katarzyna Z. Haza, Heather L. Martin, Ajinkya Rao, Amy L. Turner, Sophie E. Saunders, Britta Petersen, Christian Tiede, Kevin Tipping, Anna A. Tang, Modupe Ajayi, Thomas Taylor, Maia Harvey, Keri M. Fishwick, Thomas L. Adams, Thembaninkosi G. Gaule, Chi H. Trinh, Matthew Johnson, Alexander L. Breeze, Thomas A. Edwards, Michael J. McPherson, Darren C. Tomlinson
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
Oncogenic RAS mutants remain difficult to target with small molecules. Here, the authors show that RAS-binding Affimer proteins inhibit RAS signaling while binding diverse regions on the RAS surface, suggesting the potential to use Affimers as tools
Externí odkaz:
https://doaj.org/article/9fb0e318fb534431a1e30f0ac4d27ca1
Autor:
Kevin W. Tipping, Thembaninkosi G. Gaule, Keri M. Fishwick, Amy L. Turner, Anna A Tang, Britta Petersen, Heather L. Martin, Sophie E. Saunders, Chi H. Trinh, Darren C. Tomlinson, Ajinkya Rao, Alexander L. Breeze, Matthew D. Johnson, Thomas A. Edwards, Thomas L. Adams, Maia Harvey, Katarzyna Z. Haza, Thomas Taylor, Michael J. McPherson, Modupe Ajayi, Christian Tiede
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
'Nature Communications ', vol: 12, pages: 4045-1-4045-15 (2021)
Nature Communications
'Nature Communications ', vol: 12, pages: 4045-1-4045-15 (2021)
Nature Communications
RAS mutations are the most common oncogenic drivers across human cancers, but there remains a paucity of clinically-validated pharmacological inhibitors of RAS, as druggable pockets have proven difficult to identify. Here, we identify two RAS-binding
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d7c3a7099793492e3c58ab8d5138de3
https://doaj.org/article/9fb0e318fb534431a1e30f0ac4d27ca1
https://doaj.org/article/9fb0e318fb534431a1e30f0ac4d27ca1